Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.

NCT00728780 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Adverse Events
Pharmacokinetic Variables

Interventions

DRUG: ABT-143
DRUG: ABT-335 and rosuvastatin

Sponsor

AstraZeneca